Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Pancreatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Colorectal Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Lymphoma, Follicular 3Kidney Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Carcinoma 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoma, T-Cell, Cutaneous 2

Interventions

durvalumab 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Appendiceal Neoplasms × durvalumab × Clear all
NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Ludwig Institute for Cancer Research

Phase 1/2 Completed
67 enrolled 16 charts
GastrointestinalGynecologic

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡